HANSEN-TECHNOLOGIES
18.1.2023 10:01:41 CET | Business Wire | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water, and communications industries, is pleased to announce that it is partnering with Aidon, an established, customer-centric supplier of smart grid, smart metering, and technology services in the Nordics, to provide a fully managed solution for three distribution system operators (DSOs) in the progressive Nordic market. This collaboration comes when DSOs look to enhance their infrastructure capabilities and position themselves for the changing customer market of tomorrow.
The Aidon project covers the delivery of Hansen MDM and associated services for three major DSOs: Kymenlaakson Sähköverkko, Järvi-Suomen Energia, and PKS Sähkönsiirto. A fully managed offering, it provides outsourced meter-reading and reporting capabilities for the Finnish Datahub. With this project, Hansen further bolsters its leadership position as a technology solution provider to the energy sector, delivering cost-efficient and future-ready solutions to meet emerging market demands. Among these is the ability to process real-time five-minute data reads, a crucial aspect of the evolving market regulations. With diverse energy sources such as wind and solar coming online, production and consumption data needs to be much more real-time to maintain grid balance and enable on-demand management services. Additionally, more granular data delivers greater transparency and more actionable data for end customers, especially ‘prosumers’ who also generate energy.
Hansen MDM, part of the Hansen Suite for Energy & Utilities, is a cloud-native implementation able to process large volumes of smart-metering data, and is available in a SaaS deployment model. The cloud-native version of Hansen MDM builds on decades of experience and expertise in Nordic deployments, delivering a full-featured and mature implementation for those utilities that seek the advantages of a cloud-based implementation.
Tommi Blomberg, Chief Executive Officer, Aidon, commented: "We're in the age of digitalisation and massive data generation. This partnership with one of the Nordic's longstanding technology leaders for energy and utilities will ensure that regional DSOs have access to cutting-edge solutions capable of addressing all their smart-metering needs."
Scott Weir, Division President, Energy and Utilities for the EMEA region at Hansen, commented: "At Hansen, we are proud of our legacy in the Nordic region, continually powering transformation and infrastructural enablement for several leading energy and utilities players. With our new alliance with Aidon, leveraging the best that Hansen MDM offers, we are set to bring about a new era in customer-experience innovation in the face of a rapidly changing and dynamic marketplace."
For further information about Hansen Technologies, please visit www.hansencx.com.
About Hansen Technologies
Hansen Technologies (ASX: HSN) is a leading global software provider and services to the energy, water and communications industries. With its award-winning software portfolio, Hansen serves 600+ customers in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
About Aidon
Aidon is the leading provider of smart grid and smart metering solutions, applications and services in the Nordics. Our systems enable reliable metering and distribution of energy as well as efficient maintenance processes of distribution networks for our customers. The technology supplied by Aidon is in use in almost 4 million energy metering points in the Nordic countries. Our head office is in Jyväskylä, Finland, our Swedish office in Stockholm, the Norwegian office in Asker and the Danish office in Copenhagen.
For more information, visit https://www.aidon.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom